Citigroup’s Intellia Therapeutics NTLA Stock Holding History

Citigroup’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$362K	Buy	+30,000	New	+$375K	﹤0.01%	3935
2023 Q4	–	Sell	-5,000	Closed	-$158K	–	5810
2023 Q3	$158K	Buy	+5,000	New	+$194K	﹤0.01%	3767
2022 Q4	–	Sell	-25,000	Closed	-$1.4M	–	5899
2022 Q3	$1.4M	Buy	+25,000	New	+$1.55M	﹤0.01%	2451
2020 Q2	–	Sell	-5,600	Closed	-$68K	–	7631
2020 Q1	$68K	Sell	5,600 -20,200	-78%	-$272K	﹤0.01%	5686
2019 Q4	$378K	Buy	25,800 +7,400	+40%	+$103K	﹤0.01%	4670
2019 Q3	$246K	Buy	18,400 +6,900	+60%	+$110K	﹤0.01%	4975
2019 Q2	$188K	Buy	11,500 +8,000	+229%	+$126K	﹤0.01%	5326
2019 Q1	$60K	Sell	3,500 -100	-3%	-$1.49K	﹤0.01%	6187
2018 Q4	$49K	Sell	3,600 -18,500	-84%	-$344K	﹤0.01%	6264
2018 Q3	$633K	Buy	22,100 +10,100	+84%	+$294K	﹤0.01%	3999
2018 Q2	$328K	Buy	12,000 +3,600	+43%	+$87.2K	﹤0.01%	4532
2018 Q1	$177K	Buy	+8,400	New	+$207K	﹤0.01%	5088

Other funds holding NTLA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Citigroup's NTLA Position: Q3 2026 in Review

Citigroup reduced its Intellia Therapeutics (NTLA) stake by 43% in Q3 2026, selling an estimated $1.24M and leaving 133,950 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Citigroup first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $24.6M in Q1 2022. 147 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Citigroup held 133,950 shares of Intellia Therapeutics worth $1.62M as of Q3 2026.
Citigroup sold 99,307 Intellia Therapeutics shares in Q3 2026, an estimated $1.24M.
Intellia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2978 holding.
Citigroup first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
Citigroup's Intellia Therapeutics position peaked at $24.6M in Q1 2022.
147 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.